Business Context and Reporting Period
MIMEDX GROUP, INC. filed this Form 8-K on August 19, 2009, to report the entry into and termination of material definitive agreements. The filing concerns an Amendment and Settlement Agreement between the Registrant, its subsidiary MiMedx, Inc., and Thomas J. Graham, M.D. (along with Phantom Hand Project, LLC).
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a legal settlement and contract amendments.
Material Changes and Agreement Terms
The filing details a comprehensive restructuring of the relationship with Dr. Graham, including:
- Terminations: The Cost Recovery and Revenue Sharing Letter and the Finder's Fee Letter Agreement (both dated May 22, 2008) were terminated.
- Intellectual Property: Certain provisional patent applications not intended for pursuit by MiMedx were transferred to Dr. Graham.
- Equity Adjustments:
- Vesting of options for 250,000 shares of common stock was accelerated, with the exercise period extended to five years from issuance.
- Dr. Graham is obligated to forfeit 50,000 shares of previously issued common stock.
- Consulting Agreement Amendments:
- The scope of the "Field" and products subject to royalties were narrowed.
- A uniform royalty rate of 3% was established.
- Dr. Graham agreed to forgo 50% of consulting payments starting with the third quarter of 2009 until the agreement is assumed by an acquirer of the Level Assets.
- Disposition Proceeds Allocation: If the "Level Assets" (Level Orthopedics division) are sold on or before September 20, 2010, proceeds will be allocated as follows:
- First, to pay transaction costs.
- Second, to pay MiMedx $1,150,000.
- Third, remaining proceeds split 17.5% to the Graham Parties and 82.5% to MiMedx.
Outlook, Risks, and Contingencies
The filing acknowledges that MiMedx is actively exploring a disposition of the Level Assets. The financial impact of the agreement is contingent upon this potential sale occurring before September 20, 2010. The agreement is freely assignable by MiMedx, and the term may be extended by an assignee following a sale.
Investor Verification Checklist
- Verify the status of the Level Orthopedics division and any ongoing negotiations for its disposition.
- Confirm the impact of the 50% reduction in consulting fees on the company's operating expenses for Q3 and Q4 2009.
- Review the specific provisional patent applications transferred to Dr. Graham to assess any loss of potential IP value.
- Monitor the forfeiture of 50,000 shares and the acceleration of 250,000 options for potential dilution effects.